[1] SHAFI T, POWE NR, MEYER TW, et al.Trimethylamine N-Oxide and cardiovascular events in hemodialysis patients[J]. J Am Soc Nephrol, 2017, 28(1): 321-331. [2] SARAN R, ROBINSON B, ABBOTT KC, et al.US renal data system 2016 annual data report: epidemiology of kidney disease in the United States[J]. Am J Kidney Dis, 2017, 69(3): A7-A8. [3] Chinese Society of Nephrology Expert Cooperation Group of Chronic Kidney Disease Hypertension Treatment. Practice guidelines for α/β blockers in the treatment of hypertension in chronic kidney disease[J]. Chinese Medical Journal(中华医学杂志) , 2013, 93(48): 3812-3816. [4] Chinese Expert Consensus Group on Application of β-adrenergic Receptor Blockers in Standardized Treatment of Coronary Heart Disease. Chinese expert consensus on the standardized treatment of coronary heart disease with β-adrenergic receptor blockers[J]. Chinese Journal of Circulation(中国循环杂志) , 2020, 35(2): 108-123. [5] KONSTANTINIDIS I, NADKARNI GN, YACOUB R, et al.Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review[J]. JAMA Intern Med, 2016, 176(1): 121-124. [6] YANG XL, LI JX, HU DS, et al.Predicting the 10-year risks of atherosclerotic cardiovascular disease in chinese population: The China-PAR Project (Prediction for ASCVD Risk in China)[J]. Circulation, 2016, 134(19):1430-1440. [7] COZZOLINO M, MANGANO M, STUCCHI A, et al. Cardiovascular disease in dialysis patients[J]. Nephrol Dial Transplant, 2018, 33(3): iii28-iii34. [8] MAYER CC, MATSCHKAL J, SARAFIDIS PA, et al.Association of ambulatory blood pressure with all-cause and cardiovascular mortality in hemodialysis patients: effects of heart failure and atrial fibrillation[J]. J Am Soc Nephrol, 2018, 29(9): 2409-2417. [9] WU HL.Efficacy analysis of metoprolol and carvedilol in the treatment of chronic heart failure[J]. Medical Innovation in China(中国医学创新) ,2018, 32(15): 43-46. [10] WANG ZH.Comparison of short-term and long-term efficacy of two β -blockers in the treatment of chronic heart failure[J]. Journal of Clinical Rational Drug Use(临床合理用药杂志) , 2016, 9(16): 58-61. [11] TIEU A, VELENOSI TJ, KUCEY AS, et al.β-blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial[J]. Clin J Am Soc Nephrol, 2018, 13(4): 604-611. [12] ASSIMON MM, BROOKHART MA, FINE JP, et al.A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis[J]. Am J Kidney Dis, 2018, 72(3): 337-348. [13] ZHANG YP, ZHAO LS.Observation on the curative effect of metoprolol in the treatment of severe heart failure[J]. Electronic Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular Disease(中西医结合心血管病电子杂志) , 2020, 8(22): 39-40. [14] FENG WH.Effect of metoprolol succinate on cardiac function in patients with coronary heart disease and heart failure[J]. Electronic Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular Disease(中西医结合心血管病电子杂志) , 2020, 8(29): 53-197. [15] HANNA F, LORELLA T, TOBIAS T, et al.Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure[J]. Clin Res Cardiol, 2017, 106(9): 711-721. [16] ZHOU H, SIM JJ, SHI JX, et al.β-blocker use and risk of mortality in heart failure patients initiating maintenance dialysis[J]. American Journal of Kidney Diseases, 2020, 3(20): 1001-1009. [17] MA JC, DU LB, LIANG XL, et al.Effect of carvedilol on cardiac function in patients with diabetic nephropathy undergoing hemodialysis[J]. Journal of Kidney Disease and Kidney Transplantation on Dialysis(肾脏病与透析肾移植杂志) , 2018, 27(2): 147-150. |